Search

Your search keyword '"Castañeda, S."' showing total 1,056 results

Search Constraints

Start Over You searched for: Author "Castañeda, S." Remove constraint Author: "Castañeda, S."
1,056 results on '"Castañeda, S."'

Search Results

52. Endothelin-1 for the differential diagnosis between interstitial lung disease associated with autoimmune diseases and idiopathic pulmonary fibrosis

58. Grasa sobrepasante: Aplicaciones y su proceso de obtención para la alimentación de rumiantes en el trópico

59. Evaluación citológica y microbiológica de lavados uterinos en bovinos con problemas reproductivos (estudio preliminar)

60. IDENTIFICACIÓN DE NUEVAS REGIONES GENÉTICAS ASOCIADAS A LA ARTERITIS DE CÉLULAS GIGANTES MEDIANTE GWAS.

61. Diagnóstico clínico-microbiológico de otitis externa en caninos de Bogotá – Colombia

63. POS0806 OPTIMIZATION OF TOCILIZUMAB THERAPY IN GIANT CELL ARTERITIS. A MULTICENTER REAL-LIFE STUDY OF 471 PATIENTS.

64. POS0804 TOCILIZUMAB IN LARGE-VESSEL GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS: MULTICENTRIC OBSERVATIONAL COMPARATIVE STUDY

65. POS0795 EPIDEMIOLOGY, DIAGNOSIS AND CLINICAL CHARACTERISTICS OF GIANT CELL ARTERITIS IN PATIENTS INCLUDED IN THE ARTESER MULTICENTER STUDY

66. AB0145 IgA VASCULITIS AND IgA NEPHROPATHY SHARE A SIMILAR IL33-IL1RL1 ASSOCIATION PATTERN

67. POS0802 INVOLVEMENT OF THE AORTA AND/OR ITS MAIN BRANCHES IN GIANT CELL ARTERITIS. TREATMENT WITH TOCILIZUMAB

68. POS0817 TOCILIZUMAB IN NEWLY DIAGNOSED GIANT CELL ARTERITIS VERSUS REFRACTORY/RECURRENT GIANT CELL ARTERITIS; MULTICENTER STUDY OF 471 PATIENTS OF CLINICAL PRACTICE

69. AB0069 ASSOCIATION OF NUCLEAR FACTOR OF ACTIVATED T CELLS CYTOPLASMIC 1 (NFATc1) EXPRESSION WITH CARDIOVASCULAR RISK IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS

70. AB0231 PROGNOSTIC UTILITY OF METACARPAL BONE MINERAL DENSITY MEASUREMENT IN PATIENTS WITH RECENT-ONSET ARTHRITIS BY ASSESSMENT OF RADIOGRAPHIC PROGRESSION AT 2-YEAR FOLLOW-UP

71. POS0327 IRISIN: A NEW MARKER OF SUBCLINICAL ATHEROSCLEROSIS, CARDIOVASCULAR RISK AND DISEASE ACTIVITY IN AXIAL SPONDYLOARTHRITIS?

72. POS0828 BIOLOGIC THERAPY IN REFRACTORY PARENCHYMAL AND NON-PARENCHYMAL NEUROBEHÇET DISEASE: NATIONAL MULTICENTER STUDY

73. AB1367 PET ASSESSMENT OF THE EFFECTIVENESS OF TOCILIZUMAB IN GIANT CELL ARTERITIS. STUDY OF 101 PATIENTS FROM CLINICAL PRACTICE

74. POS0272 INTRAVENOUS VERSUS SUBCUTANEOUS TOCILIZUMAB IN A SERIES OF 471 PATIENTS WITH GIANT CELL ARTERITIS

75. AB0638 INTRAVENOUS IMMUNOGLOBULIN IN ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS. STUDY OF 28 CASES FROM A SINGLE UNIVERISTARY HOSPITAL AND LITERATURE REVIEW

76. POS0801 VISUAL INVOLVEMENT AND PERMANENT VISUAL LOSS IN GIANT CELL ARTERITIS: PREDICTIVE FACTORS

77. AB0146 BAFF, APRIL y BAFFR: DIFFERENTIAL BIOMARKERS BETWEEN IgA VASCULITIS AND IgA NEPHROPATHY?

78. Gene Network of Susceptibility to Atypical Femoral Fractures Related to Bisphosphonate Treatment

79. ABATACEPT IN MONOTHERAPY VERSUS COMBINED IN INTERSTITIAL LUNG DISEASE OF RHEUMATOID ARTHRITIS. MULTICENTER STUDY OF 263 CAUCASIAN PATIENTS

80. Bone loss induced by cancer treatments in breast and prostate cancer patients

90. Influence of the IL17A locus in giant cell arteritis susceptibility

91. Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMAtology (CARMA) prospective study-results at 5 years of follow-up

92. Vertebral fractures are increased in rheumatoid arthritis despite recent therapeutic advances: a case-control study

93. Role of IRF5 in the pathogenesis of immunoglobulin-A vasculitis

95. INFLUENCE OF INTERSTITIAL LUNG DISEASE DURATION ON THE TREATMENT OF RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 392 PATIENTS WITH ABATACEPT.

100. AB0396 RAPID IMPROVEMENT IN CYSTOID MACULAR EDEMA WITH HIGH DOSE INTRAVENOUS METHYLPREDNISOLONE IN NON-INFECTIOUS UVEITIS OF DIFFERENT IMMUNE MEDIATED INFLAMMATORY DISEASES

Catalog

Books, media, physical & digital resources